USA - engelsk - NLM (National Library of Medicine)

method pharmaceuticals, llc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 0.625 mg - esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women with any of the following conditions: 1.       known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2.       known or suspected estrogen-dependent ne

USA - engelsk - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 1.25 mg - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: esterified estrogens and methyltestosterone full and half-strength tablets should not be used in women with any of the following conditions: methyltestosterone should not be used in: methyltestosterone is classified as a schedule iii controlled substance under the anabolic steroids act of 1990.

Israel - engelsk - Ministry of Health

padagis israel agencies ltd, israel - estriol - cream - estriol 0.1 % - estriol - for the treatment of vulvo-vaginal complaints related to estrogen deficiency.

USA - engelsk - NLM (National Library of Medicine)

pharmacia and upjohn company - estropipate (unii: svi38uy019) (estropipate - unii:svi38uy019) - cream - 1.5 mg in 1 g - ogen vaginal cream is indicated for the treatment of vulval and vaginal atrophy. estrogens should not be used in individuals with any of the following conditions: - known or suspected pregnancy (see boxed warning ). estrogens may cause fetal harm when administered to a pregnant woman. - undiagnosed abnormal genital bleeding. - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - active thrombophlebitis or thromboembolic disorders. ogen vaginal cream (estropipate) is contraindicated in patients hypersensitive to its ingredients.

Canada - engelsk - Health Canada

insight pharmaceuticals, llc - miconazole nitrate - cream - 2% - miconazole nitrate 2% - azoles

Canada - engelsk - Health Canada

taro pharmaceuticals inc - miconazole nitrate - cream - 2% - miconazole nitrate 2% - azoles

Canada - engelsk - Health Canada

insight pharmaceuticals, llc - miconazole nitrate - cream - 4% - miconazole nitrate 4% - azoles

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg/g - cream - excipient ingredients: sodium hydroxide; stearyl alcohol; lactic acid; cetyl esters wax; purified water; chlorhexidine hydrochloride; sorbitan monostearate; octyldodecanol; glycerol; polysorbate 60; cetyl alcohol - indication as at 6 july 2016: vulvo-vaginal complaints due to oestrogen deficiency associated with the climacteric and the postmenopause or after ovariectomy: ? atrophic vaginitis ? pruritus vulvae ? dyspareunia due to vulvo-vaginal atrophy ? as auxiliary therapy in the treatment of vaginal infections ? as pre-operative therapy for vulvo-vaginal surgery and during subsequent convalescence ? ulcers in cases of prolapse of the uterus or vagina ? to avoid misinterpretation of a cytological smear

USA - engelsk - NLM (National Library of Medicine)

dispensing solutions, inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.3 mg - prempro or premphase therapy should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active deep vein thrombosis, pulmonary embolism or a history of these conditions - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions - known liver dysfunction or disease - known thrombophilic disorders (e.g., protein c, protein s, or antithrombin deficiency) - known or suspected pregnancy prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing mothers has been shown to decrease the quanti

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.3 mg - prempro or premphase therapy should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active deep vein thrombosis, pulmonary embolism or a history of these conditions - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions - known liver dysfunction or disease - known thrombophilic disorders (e.g., protein c, protein s, or antithrombin deficiency) - known or suspected pregnancy prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing mothers has been shown to decrease the quanti